ARX8203 has showed positive and significant safety profile in GI toxicity studies compared with Diclofenac and Indomethacin, two very popular and currently marketed NSAIDs.
AlphaRx has developed three formulations using ARX8203, an injectable formulation for post-surgical pain, an oral capsule for chronic pain and an ophthalmic formulation for ocular inflammation.
In total, AlphaRx has eight further US patent applications pending in different stages of examination and it is confident that this is the first of many patents yet to receive allowance.